LIPTIDE Trademark

Trademark Overview


On Monday, July 30, 2018, a trademark application was filed for LIPTIDE with the United States Patent and Trademark Office. The USPTO has given the LIPTIDE trademark a serial number of 79243223. The federal status of this trademark filing is REGISTERED as of Tuesday, April 28, 2020. This trademark is owned by Nanogenics Limited. The LIPTIDE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutica...
liptide

General Information


Serial Number79243223
Word MarkLIPTIDE
Filing DateMonday, July 30, 2018
Status700 - REGISTERED
Status DateTuesday, April 28, 2020
Registration Number6039104
Registration DateTuesday, April 28, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 19, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNanogenics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressLondon N12 0DR
GB

Party NameNanogenics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressLondon N12 0DR
GB

Party NameNanogenics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLondon N12 0DR
GB

Trademark Events


Event DateEvent Description
Saturday, September 26, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, September 8, 2020FINAL DISPOSITION NOTICE SENT TO IB
Saturday, September 5, 2020FINAL DISPOSITION PROCESSED
Tuesday, July 28, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, April 28, 2020REGISTERED-PRINCIPAL REGISTER
Friday, April 3, 2020NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, March 18, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 18, 2020NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, February 11, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2020PUBLISHED FOR OPPOSITION
Friday, February 7, 2020NOTIFICATION PROCESSED BY IB
Wednesday, January 22, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 22, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 22, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 3, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 26, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 26, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 26, 2019TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, June 28, 2019NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, June 28, 2019FINAL REFUSAL E-MAILED
Friday, June 28, 2019FINAL REFUSAL WRITTEN
Friday, June 7, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 7, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 3, 2019ASSIGNED TO LIE
Wednesday, May 29, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 11, 2019NEW REPRESENTATIVE AT IB RECEIVED
Friday, December 28, 2018REFUSAL PROCESSED BY IB
Friday, December 7, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 7, 2018REFUSAL PROCESSED BY MPU
Saturday, November 24, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, November 23, 2018NON-FINAL ACTION WRITTEN
Thursday, November 15, 2018ASSIGNED TO EXAMINER
Tuesday, October 23, 2018APPLICATION FILING RECEIPT MAILED
Friday, October 19, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 18, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB